DEA Emergency Order: Glasgow Drug Distributor Faces Immediate Suspension

The Drug Enforcement Administration issued an immediate suspension order on January 14, 2025, against Glasgow Drug Company, a Kentucky-based wholesale drug distributor, effective immediately. The emergency action suspends the company's DEA Certificate of Registration under 21 U.S.C. § 824(d), barring it from handling controlled substances pending final administrative proceedings.

Regulatory Authority for Immediate Suspension

DEA immediate suspension orders operate under 21 U.S.C. § 824(d), which grants the Attorney General authority to suspend a DEA registration when continuation "would constitute an imminent danger to the public health or safety." Unlike standard revocation proceedings under 21 U.S.C. § 824(a), immediate suspensions take effect without prior hearing when DEA determines that delay would pose unacceptable risk.

The suspension order against Glasgow Drug Company cites "substantial evidence of diversion of controlled substances" and failure to maintain effective controls against diversion as required under 21 CFR § 1301.71. DEA's order notes that the distributor continued operations despite documented gaps in inventory reconciliation procedures and suspicious order monitoring systems required under the Controlled Substances Act.

Violations Leading to Emergency Action

According to DEA's suspension order, Glasgow Drug Company failed to implement adequate safeguards required for wholesale drug distributors handling Schedule II-V controlled substances. Specific deficiencies cited include:

• Inventory reconciliation failures: The distributor could not account for discrepancies totaling over 50,000 dosage units of hydrocodone combination products (Schedule II) across a six-month period
• Suspicious order monitoring deficiencies: Glasgow Drug Company filled orders flagged as statistically anomalous without documented investigation or justification, violating the "corresponding responsibility" doctrine under 21 CFR § 1301.74(b)
• Customer due diligence gaps: The distributor supplied controlled substances to three pharmacy customers whose DEA registrations had expired, a violation of 21 CFR § 1301.26

The order documents 47 instances where Glasgow Drug Company shipped controlled substances to addresses not matching the registered location on customer DEA certificates—a red flag for diversion that distributors are required to investigate under DEA's 2017 guidance on distributor due diligence.

Precedent and Enforcement Context

DEA emergency suspension orders against wholesale drug distributors remain relatively rare but carry severe operational consequences. Between 2020 and 2024, DEA issued 12 immediate suspension orders against distributors, compared to 189 suspension orders issued to individual practitioners and pharmacies during the same period. The lower frequency reflects the wholesale channel's smaller universe of registrants—approximately 5,800 DEA-registered wholesale drug distributors operate nationwide compared to over 70,000 retail pharmacies.

However, when DEA does act against distributors, the agency typically pursues immediate suspension rather than standard show-cause proceedings. Of the 12 distributor suspensions issued since 2020, 10 involved immediate suspension orders citing imminent public health danger, indicating DEA's assessment that distributor diversion poses systemic risk to the supply chain.

Impact on Wholesale Drug Distributor Operations

Glasgow Drug Company's suspension immediately terminates its ability to purchase, possess, or distribute any controlled substances. The company must return or transfer all Schedule II-V inventory to another DEA registrant within 14 days under 21 CFR § 1301.52. Customers who previously sourced controlled substances from Glasgow Drug Company must identify alternative suppliers with active DEA registrations and equivalent state wholesale drug distributor licensure.

For the broader distributor sector, this enforcement action reinforces DEA's expectations for suspicious order monitoring programs that go beyond automated threshold alerts. DEA's order specifically criticizes Glasgow Drug Company for treating its monitoring system as a "check-box compliance exercise" rather than implementing the substantive due diligence inquiry required when red flags emerge. Distributors must document investigation procedures, including customer contact, order history review, and registration verification, when filling orders that deviate from established patterns.

The suspension order also highlights the heightened enforcement environment for controlled substance distributors following the January 2024 DEA rule on automated suspicious order monitoring systems (88 FR 85261). That rule codified distributor obligations to halt shipments pending investigation when orders trigger algorithmic flags—a requirement Glasgow Drug Company allegedly failed to meet in at least 23 documented instances.

What ColdChainCheck Data Shows

ColdChainCheck does not currently track DEA registration status or controlled substance compliance signals in entity scores. DEA registration data remains restricted under the Ryan Haight Online Pharmacy Consumer Protection Act's confidentiality provisions, and ColdChainCheck has applied for research data access through DEA's Request for Data Access (RDA) process. Entity compliance scores (average: 51/100 across 1,275 tracked distributors) reflect FDA registration, state licensure, NABP accreditation, recall history, and warning letter records—but not DEA standing.

Of the 1,275 wholesale drug distributors in ColdChainCheck's directory, approximately 800-900 likely hold DEA registrations authorizing controlled substance distribution based on state license classifications. However, without direct DEA data integration, ColdChainCheck cannot verify active registration status or flag entities subject to suspension orders like the Glasgow Drug Company action.

This data gap matters for procurement and vendor qualification teams: an entity may score 75/100 in ColdChainCheck's methodology (reflecting clean FDA and state records) while simultaneously facing DEA enforcement invisible to the directory. Until DEA registration data becomes publicly queryable or available through data-sharing agreements, compliance officers must independently verify DEA status for any distributor handling Schedule II-V products.

Practical Steps for Compliance Officers

• Verify DEA registration directly: Contact trading partners to request current DEA Certificate of Registration copies. Cross-reference the registration number against the DEA registrant search tool at apps.deadiversion.usdoj.gov before placing controlled substance orders.

• Document suspicious order monitoring: Review internal procedures for handling distributor red flags. If your pharmacy or hospital submits orders that deviate from historical patterns (volume spikes, frequency changes, product mix shifts), expect legitimate distributors to contact you for justification before shipping. Distributors who fill anomalous orders without inquiry may face enforcement risk.

• Check state licensure independently: Use ColdChainCheck's directory to verify that distributors supplying controlled substances hold active state wholesale drug distributor licenses. State boards of pharmacy typically list license status, expiration dates, and disciplinary actions—complementary data to DEA registration.

• Monitor for suspension announcements: DEA publishes immediate suspension orders in the Federal Register and on its Diversion Control Division website. Set alerts for "immediate suspension order" + "wholesale distributor" to track enforcement actions affecting the supply chain. ColdChainCheck's compliance guides will cover significant distributor enforcement developments as they occur.

Disclaimer: This article is for informational purposes only and does not constitute legal or regulatory advice. Compliance officers should verify DEA registration status directly with the Drug Enforcement Administration and consult legal counsel regarding controlled substance distributor requirements.